1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
13 citations
,
September 2017 in “Life sciences” Androgens may influence bladder cancer progression by affecting cellular behavior.
728 citations
,
August 1996 in “The New England Journal of Medicine” Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
September 2018 in “The Journal of Urology”
June 2019 in “Reactions Weekly” November 2018 in “Studies in Medical Sciences”
13 citations
,
September 2011 in “International Urology and Nephrology”
28 citations
,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
39 citations
,
January 1980 in “Dermatology” Cyproterone acetate was effective in treating acne, hirsutism, and alopecia with few side effects.
1 citations
,
July 2013 in “Clinical Drug Investigation” 20 citations
,
December 2015 in “Der Urologe” Combining medications is more effective for treating benign prostatic syndrome symptoms.
1 citations
,
May 2015 in “Journal of The American Academy of Dermatology” Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
8 citations
,
January 1991 in “European Urology” Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
67 citations
,
January 1987 in “The Journal of urology/The journal of urology” New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.
January 2019 in “Nihon Yakuri Gakkai nenkai yoshishu” Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
1054 citations
,
February 1998 in “The New England Journal of Medicine” Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
June 2014 in “The Journal of Urology” January 2016 in “ISBN: 978-84-608-9184-0”
1 citations
,
June 2020 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with dutasteride may be a promising alternative treatment for hair loss.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” Finasteride helps treat prostate issues and may prevent prostate cancer in high-risk men.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
14 citations
,
January 1980 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Both treatments reduced androgen levels and hair growth in women with hirsutism.
April 2012 in “The Journal of Urology” Finasteride therapy reduces PSA levels and prostate size, helping diagnose prostate cancer.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
Finasteride and dutasteride might lower melanoma risk.